KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors

Cited by (1,002)

Items 701–800 of 1,002

1. Invasive Stratified Mucin-producing Carcinoma (ISMC) of the Uterine Cervix: Clinicopathological and Molecular Characteristics With Special Emphasis on the First Description of Consistent Programmed Death-ligand 1 (PD-L1) Over-expression
   Sangjoon Choi, So‐Woon Kim, Hyun Soo Kim · 2021 · Cancer Genomics & Proteomics
2. New Strategies and Combinations to Improve Outcomes in Immunotherapy in Metastatic Non-Small-Cell Lung Cancer
   Lucy Corke, Adrian G. Sacher · 2021 · Current Oncology
3. Pathogenic signaling in multiple myeloma
   Arnold Bolomsky, Ryan M. Young · 2022 · Seminars in Oncology
4. Reflections on drug resistance to KRAS inhibitors and gene silencing/editing tools for targeting mutant KRAS in cancer treatment
   Zhaoyong Han, Ding Zhou, JiaMan Wang, Bruce Jiang, XiYu Liu · 2022 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
5. Morphological and Molecular Characterization of KRAS G12C-Mutated Lung Adenocarcinomas
   Radu Pîrlog, Nicolas Piton, Aude Lamy, Florian Guisier, Ioana Berindan‐Neagoe, Jean‐Christophe Sabourin, Florent Marguet · 2022 · Cancers
6. Multiplex Droplet Digital PCR Assay for Detection of MET and HER2 Genes Amplification in Non-Small Cell Lung Cancer
   Igor P. Oscorbin, Maria A. Smertina, Ksenia A. Pronyaeva, Mikhail Evgenyevich Voskoboev, U. A. Boyarskikh, Кечин Андрей Андреевич, Ирина Анатольевна Демидова, М. Л. Филипенко · 2022 · Cancers
7. A retrospective study for prognostic significance of type II diabetes mellitus and hemoglobin A1c levels in non-small cell lung cancer patients treated with pembrolizumab
   Yinchen Shen, Jiaqi Li, Huiping Qiang, Yuqiong Lei, Qing Chang, Runbo Zhong, Giulia Maria Stella, Francesco Gelsomino, Yeon Wook Kim, Afaf Abed et al. · 2022 · Translational Lung Cancer Research
8. Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM)
   Davide Ciardiello, Cinzia Chiarazzo, Vincenzo Famiglietti, Angela Damato, Carmine Pinto, Maria Giulia Zampino, Grazia Castellano, Lorenzo Gervaso, Alberto Zaniboni, Ester Oneda et al. · 2022 · ESMO Open
9. How to manage KRAS G12C-mutated advanced non-small-cell lung cancer
   Biagio Ricciuti, Alessia Mira, Elisa Andrini, Pietro Scaparone, Sandra Vietti Michelina, Federica Pecci, Luca Cantini, Andrea De Giglio, Giuseppe Lamberti, Chiara Ambrogio et al. · 2022 · Drugs in Context
10. Molecular profiling and prognostic biomarkers in chinese non-small cell lung cancer cohort
    Fangfang Shen, Wei Guo, Xia Song, Bei Wang · 2023 · Diagnostic Pathology
11. Progress of research on molecular targeted therapies for colorectal cancer
    Shilin Huang, Jiazhou Ye, Xing Gao, Xi Huang, Julu Huang, Lu Lu, Cheng Lu, Yongqiang Li, Min Luo, Mingzhi Xie et al. · 2023 · Frontiers in Pharmacology
12. Pharmacokinetics of the KRASG12C inhibitor adagrasib is limited by CYP3A and ABCB1, and influenced by binding to mouse plasma carboxylesterase 1c
    Nancy H.C. Loos, Irene A. Retmana, Jamie Rijmers, Yaogeng Wang, Changpei Gan, Maria Cristina Lebre, Rolf W. Sparidans, Jos H. Beijnen, Alfred H. Schinkel · 2023 · Biomedicine & Pharmacotherapy
13. Two decades of research toward the treatment of locally advanced and metastatic pancreatic cancer: Remarkable effort and limited gain
    Celine Yeh, Susan Elaine Bates · 2021 · Seminars in Oncology
14. Distribution of genetic alterations in high-risk early-stage cervical cancer patients treated with postoperative radiation therapy
    Naoya Murakami, Yuka Asami, Hiroshi Yoshida, Daisuke Takayanagi, Sou Hirose, Ikumi Kuno, Kazuaki Takahashi, Maiko Matsuda, Yoko Shimada, Shotaro Yamano et al. · 2021 · Scientific Reports
15. Chaperone-Mediated Autophagy Markers LAMP2A and HSPA8 in Advanced Non-Small Cell Lung Cancer after Neoadjuvant Therapy
    Tereza Losmanová, Philipp Zens, Amina Scherz, Ralph Alexander Schmid, Mario P. Tschan, Sabina Berezowska · 2021 · Cells
16. Absorption, Distribution, Metabolism, and Excretion of [14C]-Sotorasib in Rats and Dogs: Interspecies Differences in Absorption, Protein Conjugation and Metabolism
    Upendra P. Dahal, Brooke M. Rock, John Rodgers, Xiaomeng Shen, Zhe Wang, Jan L. Wahlstrom · 2022 · Drug Metabolism and Disposition
17. All Optimal Dosing Roads Lead to Therapeutic Drug Monitoring—Why Take the Slow Lane
    Jan Hendrik Beumer, Edward Chu, Salvatore J. Salamone · 2022 · JAMA Oncology
18. Metabolic Phenotypes, Dependencies, and Adaptation in Lung Cancer
    Gina M. DeNicola, David B. Shackelford · 2021 · Cold Spring Harbor Perspectives in Medicine
19. Comprehensive structure-function analysis reveals gain- and loss-of-function mechanisms impacting oncogenic KRAS activity
    Jason J. Kwon, Julien Dilly, Shengwu Liu, Eejung Kim, Yuemin Bian, Srisathiyanarayanan Dharmaiah, Timothy H. Tran, Kevin S. Kapner, Seav Huong Ly, Xiaoping Yang et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
20. Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C -mutant Colorectal Cancer
    Khawaja, Hajrah, Briggs, Rebecca, Latimer, Cheryl H., Rassel, Mustasin, Griffin, Daryl, Hanson, Lyndsey, Bardelli, Alberto, Di Nicolantonio, Frederica, McDade, Simon S., Scott, Christopher J. et al. · 2023 · Molecular Cancer Therapeutics
21. Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma
    Christenson, Eric S., Lim, Su Jin, Durham, Jennifer, De Jesus-Acosta, Ana, Bever, Katherine, Laheru, Daniel, Ryan, Amy, Agarwal, Parul, Scharpf, Robert B., Le, Dung T. et al. · 2022 · Cancer Research Communications
22. Gastrointestinal cancer: molecular pathogenesis and targeted therapy
    Yang Jin, Xiaobo He, Yanfeng Wu · 2025 · Molecular Biomedicine
23. Targeting KRAS G12D : Advances in Inhibitor Design
    Kaiyin Shi, Amin Li · 2025 · Thoracic Cancer
24. IASLC Update on Classification of Pulmonary Neuroendocrine Neoplasms
    Mary Beth Beasley, Yasushi Yatabe, Mauro PAPOTTI, Wendy A. Cooper, Jules L. Derks, Lynnette Fernandez‐Cuesta, Atsuko Kasajima, Sylvie Lantuéjoul, Giuseppe Pelosi, Natasha Rekhtman et al. · 2026 · Journal of Thoracic Oncology
25. Genomic landscape of clinically advanced KRAS wild-type pancreatic ductal adenocarcinoma
    Prashanth Ashok Kumar, Serenella Serinelli, Daniel J. Zaccarini, Richard S.P. Huang, Natalie A. Danziger, Tyler Janovitz, Alina Basnet, Abirami Sivapiragasam, Stephen L. Graziano, Jeffrey S. Ross · 2023 · Frontiers in Oncology
26. Innovative drugs promote precision cancer therapy
    Xuan Huang, Mengxuan Zhu, Ruoxue Chen, Junjie Ni, Wenrui Zhao, Song Li, Xiaoling Lü, Heng Jiao, Xin Cao · 2023 · Clinical Cancer Bulletin
27. Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With KRAS G12C -Mutated Non–Small Cell Lung Cancer: A Case Series and Literature Review
    Jia Luo, Narjust Florez, Anjali Donnelly, Yanyan Lou, Kevin Lu, Patrick C. Ma, Alexander I. Spira, Debra L. Ryan, Hatim Husain · 2024 · JCO Precision Oncology
28. Molecular Landscape and Therapeutic Strategies against Colorectal Cancer
    Aakash Patel, Pat Gulhati · 2024 · Cancers
29. Decoding KRAS dynamics: Exploring the impact of mutations and inhibitor binding
    Divya Pandey, Kuldeep Kumar Roy · 2024 · Archives of Biochemistry and Biophysics
30. Identification of Somatic Genetic Variants in Superficial Vascular Malformations by Liquid Biopsy in a Cohort of 88 Patients from a French Hospital
    Franck Neil El Sissy, Annouk Bisdorff, Alexandre Perrier, Erell Guillerm, Jérôme Alexandre Denis, Loëtitia Favre, Mathilde Aubertin, Mélanie Eyries, Florence Coulet · 2025 · Molecular Diagnosis & Therapy
31. Reversible Small Molecule Multivariant Ras Inhibitors Display Tunable Affinity for the Active and Inactive Forms of Ras
    Charles Parry, Francesca Pellicano, Alexander W. Schüttelkopf, Kim S. Beyer, Justin F. Bower, Amy Bryson, Kenneth Cameron, Nichole M. Cerutti, Jonathan P. Clark, Stuart C. Davidson et al. · 2025 · Journal of Medicinal Chemistry
32. TopCysteineDB: A Cysteinome-wide Database Integrating Structural and Chemoproteomics Data for Cysteine Ligandability Prediction
    Michele Bonus, Julian Greb, Jaimeen D. Majmudar, Markus Boehm, Magdalena Korczynska, Azadeh Nazemi, Alan M. Mathiowetz, Holger Gohlke · 2025 · Journal of Molecular Biology
33. Colon carcinoma presenting as ovarian metastasis
    Paul Geraeds Kemps, Mijke Bol, Ernst J.A. Steller, Lisa M. H. de Pont, Cynthia Holterhues, Leander van Gerven, Wendela Kolkman · 2021 · Radiology Case Reports
34. KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor
    Roberto Serna‐Blasco, Estela Sánchez‐Herrero, Sandra Sanz‐Moreno, Alejandro Rodríguez-Festa, Eva García‐Veros, Marta Casarrubios, Belén Sierra‐Rodero, Raquel Laza Briviesca, Alberto Cruz‐Bermúdez, Xabier Mielgo-Rubio et al. · 2021 · ESMO Open
35. Response to immunotherapy in KRAS G12C mutated NSCLC: a single-centre retrospective observational study
    Carolina Sciortino, Valentina Viglialoro, Massimo Nucci, Mariam Grazia Polito, Enrico Cortesi, Alain Jonathan Gelibter, Paola Gazzaniga, Chiara Nicolazzo, Marco Siringo, S Caponnetto · 2022 · Oncotarget
36. Synthetic Vulnerabilities in the KRAS Pathway
    Marta Román, Elizabeth E. Hwang, Alejandro Sweet-Cordero · 2022 · Cancers
37. Application of histology-agnostic treatments in metastatic colorectal cancer
    Andrea Sartore Bianchi, Alberto Giuseppe Agostara, Giorgio Patelli, Gianluca Mauri, Elio Gregory Pizzutilo, Salvatore Siena · 2022 · Digestive and Liver Disease
38. Definitive Chemoradiation and Durvalumab Consolidation for Locally Advanced, Unresectable KRAS-mutated Non-Small Cell Lung Cancer
    Matthew Z. Guo, Joseph Christopher Murray, Paola Ghanem, Khinh Ranh Voong, Russell Kenneth Hales, David S. Ettinger, Vincent K. L. Lam, Christine L. Hann, Patrick M. Forde, Julie Renee Brahmer et al. · 2022 · Clinical Lung Cancer
39. Glucocorticoid receptor and RAS: an unexpected couple in cancer
    Ion Cristian Cirstea, Herwig Peter Moll, Jan Peter Tuckermann · 2022 · Trends in Cell Biology
40. Targeting the Isoprenoid Biosynthetic Pathway in Multiple Myeloma
    Staci L. Haney, Sarah A. Holstein · 2022 · International Journal of Molecular Sciences
41. Precision Medicine in Pancreatitis: The Future of Acute Pancreatitis Care
    András Garami, Péter Jenő Hegyi · 2023 · Function
42. Current advances and development strategies of targeting son of sevenless 1 (SOS1) in drug discovery
    Jialin Wu, Xiaoxue Li, Chengyong Wu, Di Wang, Jifa Zhang · 2024 · European Journal of Medicinal Chemistry
43. Pancreatic adenocarcinoma: molecular drivers and the role of targeted therapy
    Bayan A. Al-Share, Nour Hammad, Maria Diab · 2021 · Cancer and Metastasis Reviews
44. Research on Anal Squamous Cell Carcinoma: Systemic Therapy Strategies for Anal Cancer
    Ryan Michael Carr, Zhaohui Jin, Joleen Marie Hubbard · 2021 · Cancers
45. What Is New in Biomarker Testing at Diagnosis of Advanced Non-Squamous Non-Small Cell Lung Carcinoma? Implications for Cytology and Liquid Biopsy
    Paul M Hofman · 2021 · Journal of Molecular Pathology
46. The Emerging Importance of Tumor Genomics in Operable Non-Small Cell Lung Cancer
    Harry B. Lengel, James G. Connolly, Gregory D. Jones, Raul Caso, Jian Hua Zhou, Francisco Sánchez-Vega, Brooke Mastrogiacomo, James M. Isbell, Bob T. Li, Yuan Liu et al. · 2021 · Cancers
47. KRAS-Targeted Therapies in Advanced Solid Cancers: Drug the Undruggable?
    Khalil Saleh, Manal Kordahi, Tony Felefly, Hampig Raphaël Kourié, Nadine Khalife · 2021 · Pharmacogenomics
48. KRAS, a New Target for Precision Medicine in Colorectal Cancer?
    Boilève, Alice, Smolenschi, Cristina, Lambert, Aurélien, Boige, Valérie, Delaye, Matthieu, Camilleri, Géraldine M., Tarabay, Anthony, Valéry, Marine, Fuerea, Alina, Pudlarz, Thomas et al. · 2024 · Cancers
49. Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients
    Moom Rahman Roosan, Isa Mambetsariev, Rebecca R. Pharaon, Jeremy Fricke, Angel Ray Baroz, Joseph Chao, Chen Chen, Mohd Wasim Nasser, Ramakanth Chirravuri‐Venkata, Maneesh Jain et al. · 2021 · Cancers
50. N-Heterocycles as Privileged Scaffolds in FDA Approved Different NMEs of 2021: A Review
    Faryal Chaudhry, Rubina Munir, Nayab Malik · 2022 · Letters in Organic Chemistry
51. Targeted Next-Generation Sequencing of Flat Urothelial Lesions Reveals Putative Pathobiological Pathways, Potential Biomarkers, and Rational Therapeutic Targets
    Fidele Yambayamba Musangile, Ibu Matsuzaki, Ryuta Iwamoto, Kanako Sagan, Mizuki Nishikawa, Yurina Mikasa, Yuichi Takahashi, Fumiyoshi Kojima, Isao Hara, Shin‐ichi Murata · 2023 · Modern Pathology
52. Development of a 5-FU modified miR-129 mimic as a therapeutic for non-small cell lung cancer
    Ga‐Ram Hwang, John G. Yuen, Andrew T. Fesler, Hannah Farley, John D. Haley, Jingfang Ju · 2023 · Molecular Therapy — Oncolytics
53. Performance evaluation of a CRISPR Cas9-based selective exponential amplification assay for the detection of KRAS mutations in plasma of patients with advanced pancreatic cancer
    Yue Shen, Xiaoling Zhang, Li-Yi Zhang, Zuoying Zhang, Bao Lyu, Qian Lai, Qinglin Li, Yuhua Zhang, Jieer Ying, Jinzhao Song · 2023 · Journal of Clinical Pathology
54. Small molecule anticancer drugs approved during 2021–2022: Synthesis and clinical applications
    T. N. Rekha, Arifullah Mohammed · 2024 · European Journal of Medicinal Chemistry
55. Tumour-reactive plasma cells in antitumour immunity: current insights and future prospects
    Peng Chen, Yiwei Chu, Ronghua Liu · 2024 · Immunotherapy Advances
56. Resistance to KRAS inhibition in advanced non-small cell lung cancer
    Katherina Bernadette Sreter, Maria Joana Catarata, Maximilian von Laffert, Armin Frille · 2024 · Frontiers in Oncology
57. Targeted Therapy Innovations for Melanoma
    Dahiana Amarillo, Keith T. Flaherty, Ryan Joseph Sullivan · 2024 · Hematology/Oncology Clinics of North America
58. Targeting KRAS in gynecological malignancies
    Yuanyuan Peng, Qing fan Yang · 2024 · The FASEB Journal
59. Real-World Survival Outcomes in Non–Small Cell Lung Cancer: The Impact of Genomic Testing and Targeted Therapies in a Latin American Middle-Income Country
    Juan‐Manuel Hernandez‐Martinez, Alberto Güijosa, Diana Flores‐Estrada, Graciela Cruz‐Rico, Jenny Georgina Turcott, Norma Hernández‐Pedro, Enrique Caballé‐Perez, Andrés Felipe Cardona, Oscar G. Arrieta · 2024 · JCO Global Oncology
60. Recent Anti-KRASG12D Therapies: A “Possible Impossibility” for Pancreatic Ductal Adenocarcinoma
    Navid Sobhani, Matteo Pittacolo, Alberto D’Angelo, Giovanni Marchegiani · 2025 · Cancers
61. KRAS G12V mutation-selective requirement for ACSS2 in colorectal adenoma formation
    Konstantin Budagyan, Alexa Christine Cannon, Adam G. Chatoff, Dorothy Benton, Alison Kurimchak, Daniela Araiza‐Olivera, Anastasiia Gerasimova, Nathaniel W. Snyder, James S. Duncan, Cristina Uribe‐Alvarez et al. · 2025 · Cell Reports
62. Targeting USP47 enhances the efficacy of KRAS inhibitor in KRASG12C mutated non-small cell lung cancer by controlling deubiquitination of c-Myc
    H. Y. Shin, SuA Hwang, Jeong Hyun Jeong, Sang Chul Shin, Yeonji Oh, Jin Hyeok Kim, Inah Hwang, Eunice EunKyeong Kim, Hyunah Choo, Eun Joo Song · 2025 · Pharmacological Research
63. Intersection between lung cancer and neuroscience: Opportunities and challenges
    Xiang Xiao, Lingli Huang, Ming Li, Quanli Zhang · 2025 · Cancer Letters
64. KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma
    Mahmoud Yousef, Abdelrahman M.G. Yousef, Mark W. Hurd, Ashwathy Balachandran Pillai, Saikat Chowdhury, Rebecca Anne Snyder, Mark Knafl, Ryan L. Lewis, Paul M. Roy, Mohammad Mahdi Fanaeian et al. · 2025 · Journal of Hematology & Oncology
65. Dose optimization in cancer drug development: Review and outcome of a multi-stakeholder workshop
    Axel G. Glasmacher, Elena Garralda, Chad J. Gwaltney, Katrin Rupalla, Chunze Li, Harald Weber · 2025 · European Journal of Cancer
66. Precision immune regulation in KRAS-mutated cancers: the final piece of the puzzle?
    Shenao Fu, Jiayao Ma, Changjing Cai, Jun Tan, Xiangying Deng, Hong Shen, Shan Zeng, Yihong Chen, Ying Han · 2025 · Journal of Experimental & Clinical Cancer Research
67. Inverted chimeric RNAi molecules synergistically cotarget MYC and KRAS in KRAS-driven cancers
    Yogitha S. Chareddy, Hayden P. Huggins, Snehasudha S Sahoo, Lyla J. Stanland, Christina Gutierrez-Ford, Kristina Marinak Whately, Lincy Edatt, Salma H. Azam, Matthew C. Fleming, Jonah Im et al. · 2025 · Journal of Clinical Investigation
68. Targeting polyamine metabolism and ferroptosis enhances the efficacy of KRAS-targeted therapy depending on KEAP1 status
    Yunyi Bian, Guangyao Shan, Guoshu Bi, Zhijie Xu, Jiaqi Liang, Yuanliang Yan, Wei Guo, Qihai Sui, Yanjun Yi, Haochun Shi et al. · 2025 · Nature Communications
69. Fluorine in Pharmaceuticals and Synthetic Strategies for Fluorine-Containing Molecules in Anticancer Drug Discovery: A Review
    Vivek Kumar, Meenu, Mohammad Shaquiquzzaman, M. Afshar Alam, Mymoona Akhter, Darakhshan Parveen, Mohammad Kaleem, Shyama Charan, Md. Khalid Saifullah, Sharba Tasneem · 2026 · Journal of Fluorine Chemistry
70. Oncogenic Kras targeting with MRTX1133 or Daraxonrasib specifically synergize with anti-CTLA4 to promote anti-tumor immunity in pancreatic cancer
    Krishnan K. Mahadevan, Ana S. Maldonado, Bingrui Li, Aaron A. Bickert, Adrian Perdyan, Shreyasee V. Kumbhar, Sujan Piya, Amari M. Sockwell, Sami J. Morse, Kent A. Arian et al. · 2026 · Nature Communications
71. Resistance mechanisms to epidermal growth factor receptor inhibitors in non-small cell lung cancer
    Kumar Prabhash, Suresh Kumar Bondili, Ravindra Nandhana, Vanita Noronha, Amit Joshi, Vijay Patil, Nandini Sharrel Menon, Anuradha Chougule, Omshree Anil Shetty, Rajiv Kumar et al. · 2020 · Cancer Research Statistics and Treatment
72. miR-193a-3p Enhanced the Chemosensitivity to Trametinib in Gallbladder Carcinoma by Targeting KRAS and Downregulating ERK Signaling
    Ganghua Yang, Qinhong Xu, Yong Wan, Lei Zhang, Zheng Wang, Fandi Meng · 2021 · Cancer Biotherapy and Radiopharmaceuticals
73. Melanoma with genetic alterations beyond the BRAF V600 mutation: management and new insights
    Gil Awada, Bart Neyns · 2022 · Current Opinion in Oncology
74. Implications of glutathione-S transferase P1 in MAPK signaling as a CRAF chaperone: In memory of Dr. Irving Listowsky
    Yoshiro Niitsu, Yasushi Sato, Tetsuji Takayama · 2022 · Proceedings of the Japan Academy Series B
75. Concordance analysis between liquid biopsy (ctDNA) and tumor DNA molecular profiles from panel-based next-generation sequencing
    Natalia Rodon Font, Yessica No Garbarino, Olga Díaz Castello, Juan Antonio Moya Amorós, Pedro Barrios Sánchez, David Coroleu Lletget, Ma Antonia Lequerica Cabello, Joan Borras Marcet, Sandra Mechó, Isabel Escape et al. · 2022 · Revista Española de Patología
76. Prognostic Significance of the Loss of Heterozygosity of KRAS in Early-Stage Lung Adenocarcinoma
    Anand Khadse, Vilde Drageset Haakensen, Laxmi Silwal‐Pandit, Julian Hamfjord, Patrick Micke, Johan Botling, Odd Terje Brustugun, Ole Christian Lingjærde, Åslaug Helland, Elin Hegland Kure · 2022 · Frontiers in Oncology
77. Drug Repurposing by Tumor Tissue Editing
    Florian Lüke, Dennis Christoph Harrer, Pan Pantziarka, Tobias Pukrop, Lina Ghibelli, Christopher Gerner, Albrecht Reichle, Daniel Heudobler · 2022 · Frontiers in Oncology
78. Chip-DSF: A rapid screening strategy for drug protein targets
    Zhao Cui, Peng Chen, Caifeng Li, Shiwen Deng, Hongjun Yang · 2022 · Pharmacological Research
79. Effects of chloroquine and hydroxychloroquine on the sensitivity of pancreatic cancer cells to targeted therapies
    James Andrew McCubrey, Stephen Lee Abrams, Matilde Y. Follo, Lucia Manzoli, Stefano Ratti, Alberto Maria Martelli, Melchiorre Cervello · 2022 · Advances in Biological Regulation
80. Comparison of genomic profiling of circulating tumor DNA in pancreaticobiliary malignancies in plasma and bile
    Hiroshi Ohyama, Yosuke Hirotsu, Kenji Amemiya, Yoshifumi Miura, Sumio Hirose, Toshio Oyama, Yuji Iimuro, Yuichiro Kojima, Rintaro Mikata, Hitoshi Mochizuki et al. · 2023 · Cancer
81. Structure-based pathogenicity relationship identifier for predicting effects of single missense variants and discovery of higher-order cancer susceptibility clusters of mutations
    Wang, Boshen, Lei, Xue, Tian, Wei, Perez-Rathke, Alan, Tseng, Yan-Yuan, Liang, Jie · 2023 · Briefings in Bioinformatics
82. Detection of clinically actionable gene fusions by next‐generation sequencing‐based RNA sequencing of non–small cell lung cancer cytology specimens: A single‐center experience with comparison to fluorescence in situ hybridization
    John Diks, Zhenya Tang, Mehmet Altan, Sarah Anderson, Hui Chen, Asif Rashid, Richard Kenneth Yang, Mark J. Routbort, Keyur Pravinchandra Patel, Gökçe Törüner et al. · 2023 · Cancer Cytopathology
83. Validated extended multiplexed LC-MS/MS assay for the quantification of adagrasib and sotorasib in human plasma, together with four additional SMIs
    Paul D. Kruithof, Yvo M. de Beer, Judith L. Gulikers, Leo M. Stolk, Lizza E.L. Hendriks, Sander Croes, Robin M.J.M. van Geel · 2023 · Journal of Chromatography B
84. A Score to Predict the Clinical Usefulness of Therapeutic Drug Monitoring: Application to Oral Molecular Targeted Therapies in Cancer
    Arthur Géraud, David Combarel, Christian Funck‐Brentano, Quentin Beaulieu, Noël Zahr, Sophie Broutin, Jean‐Philippe Spano, Christophe Massard, Benjamin Besse, Paul Gougis · 2024 · Clinical Pharmacology & Therapeutics
85. The ERK inhibitor GDC-0994 selectively inhibits growth of BRAF mutant cancer cells
    Yulu Chen, Ye Sang, Shiyong Li, Junyu Xue, Mengke Chen, Shubin Hong, Weiming Lv, Kartik Sehgal, Haipeng Xiao, Rengyun Liu · 2024 · Translational Oncology
86. Treatment of Rare Mutations in Patients with Lung Cancer
    Tarek Taha, Rasha Khoury, Ronen Mordechay Brenner, Haitam Nasrallah, Irena Shofaniyeh, Samih Yousef, Abed Agbarya · 2021 · Biomedicines
87. Novel insights into the pathogenesis and treatment of NRAS mutant melanoma
    Jeffrey W. Zhao, Carlos Galvez, Kathryn Eby Beckermann, Douglas Buckner Johnson, Jeffrey Alan Sosman · 2021 · Expert Review of Precision Medicine and Drug Development
88. Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
    Fabrice Barlési, Pascale Tomasini, Maryam Karimi, Stefan Michiels, Judith Raimbourg, Catherine Daniel, Henri Janicot, Anne Madroszyk, Clarisse Audigier-Valette, Élisabeth Quoix et al. · 2022 · Clinical Cancer Research
89. Innovative drugs bring continuous benefits to cancer patients
    Xuan Huang, Xin Cao · 2023 · The Innovation Life
90. Dose optimization of sotorasib: Has the burden of proof for the labeled dose been met?
    Sanjay Popat, Mark J. Ratain · 2024 · European Journal of Cancer
91. RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches
    Sütcüoğlu, Osman, Yıldırım, Hasan Çağrı, Almuradova, Elvina, Günenç, Damla, Yalçın, Şuayib · 2025 · Medicina
92. Discovery of RGT-018: A Potent, Selective, and Orally Bioavailable SOS1 Inhibitor for KRAS-Driven Cancers
    Fei Xiao, Kailiang Wang, Xinjuan Wang, Huijuan Li, Zhilong Hu, Xiaoming Ren, Wei Huang, Teng Feng, Lili Yao, Jing Lin et al. · 2024 · Molecular Cancer Therapeutics
93. Potent covalent irreversible inhibitor of KRAS G12C IBI351 in patients with advanced solid tumors: First-in-human phase I study
    Qing Hua Zhou, Nong Yang, Mingfang Zhao, Dingzhi Huang, Jun Zhao, Yan Yu, Ying Yuan, Longhua Sun, Xiaorong Dong, Tongmei Zhang et al. · 2024 · European Journal of Cancer
94. Advances in the Treatment of Rare Mutations in Non-Small Cell Lung Cancer
    Yanning Sun, Li Ma, Xiaofei Zhang, Zhaoxia Wang · 2024 · OncoTargets and Therapy
95. FGTI-2734 Inhibits ERK Reactivation to Overcome Sotorasib Resistance in KRAS G12C Lung Cancer
    Aslamuzzaman Kazi, Hitesh Vasiyani, Deblina Ghosh, Dipankar Bandyopadhyay, Rachit D. Shah, Vignesh Vudatha, Jose Trevino, Saı̈d M. Sebti · 2024 · Journal of Thoracic Oncology
96. Tissue-agnostic biomarkers in solid tumors: current approvals and emerging candidates
    Jinah Kim, Hye Sung Kim, Myungwoo Nam, Young Kwang Chae · 2025 · Cancer and Metastasis Reviews
97. Circulating Tumor DNA and Tissue Testing for Pancreatobiliary Tumors
    Himil J Mahadevia, Umair Majeed, Jaydeepbhai Patel, Ahmed Ahmed, Ahmed Elhariri, Douaa Albelal, Nakka Naga Malleswara Rao, Hari Krishnareddy Rachamala, Osama M. Mosalem, Debabrata Mukhopadhyay et al. · 2025 · JAMA Network Open
98. RAS-GTP Inhibition Overcomes Acquired Resistance to KRASG12C Inhibitors Mediated by Oncogenic and Wild-Type RAS Activation in Non–Small Cell Lung Cancer
    Hitendra Singh Solanki, Harshit Shah, Denis J. Imbody, Bina Desai, Ryoji Kato, Daria Miroshnychenko, Yaakov E. Stern, Anurima Majumder, Bhaswati Sarcar, Aobuli Xieraili et al. · 2025 · Cancer Research
99. KRAS-targeted therapies in cancer: novel approaches and overcoming resistance
    Daolin Tang, Guido Kroemer, Rui Kang · 2025 · BMJ Oncology
100. Melanoma: Pathogenesis and Targeted Therapy
     Yang Fu, Jie Liu, Zeming Mo, Bin Wang, Yaotiao Deng, Y. Jiang · 2026 · MedComm